- Technology enhances vaccine stability, which translates into greater potency and improved safety – and reduced costs
- Lower cost of goods & lower cold-chain requirements
- Sophisticated, nano-scale bioprocess-technology leverages natural enzymatic reaction:
- Locks vaccines in 3D shapes that maximize efficacy and prolong shelf life, reducing cold-chain requirements
- Economic engineering minimizes risks
- Compatible with standard biologics manufacturing
- Substantial synergies between programs
- Applying technology generates NCEs and supports novel composition of matter patents to enhance broad IP protection